SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to immediate reactions to its earnings call, with community sentiment appearing largely negative, citing concerns around competition and shrinking margins. Some traders anticipate further downside, while others point to a potential overreaction and possible bounce. Broader discussions include the quality of content and potential partnerships with companies like AMC.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a proposed offering of convertible senior notes, leading to concerns about dilution and funding. While some investors view this as a strategic move to secure long-term growth, others express skepticism about the company's financials. Community discussions revolve around potential catalysts, launch timelines, and whether this dip presents a buying opportunity or a sign of further decline.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its acquisition of Railbird, a prediction market platform, sparking discussions about its potential to compete with existing platforms like Kalshi and Polymarket. Community members are debating the impact of this move on DraftKings' market share and its ability to attract users from both regulated and unregulated markets. Some are optimistic about DraftKings' entry into prediction markets, while others express concern about competition and potential regulatory challenges.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

ISRG is trending due to strong earnings and raised guidance, sparking debate about its valuation and future growth potential. While some community members celebrate the positive report and anticipate further gains, others express concerns about margin pressures and potential saturation in the US market. Bullish sentiment highlights the company's leadership in robotic surgery and potential for international expansion.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to an earnings report that beat expectations but was followed by a weaker-than-expected forecast, sparking concerns about cautious commentary and potential impacts from trade tensions. The community is actively discussing whether the stock is overvalued and anticipating a significant price movement, with some expecting a bounce while others foresee further declines. Some traders believe analysts are paid to pump before ER as a tactic for unloading stock.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation about a potential acquisition, with Paramount Skydance and other major players like Netflix and Comcast reportedly showing interest. Community discussions revolve around the possibility of a bidding war and the potential buyout price, with some analysts suggesting a price range while others speculate on a higher value post-spinoff.  The news of a rejected offer has fueled debate about WBD's worth and the likelihood of a deal.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community members discuss its potential connection to the recent surge in Beyond Meat ($BYND), with some drawing parallels to the 2021 meme stock frenzy. While some investors express frustration with GameStop's performance and CEO Ryan Cohen's long-term vision, others remain optimistic about the company's future, citing improving profitability and potential for a short squeeze. The community is closely watching for any catalysts that could drive a turnaround, including developments related to power packs and collectibles.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

NERV is trending due to a secured $200 million financing deal aimed at advancing its schizophrenia treatment, roluperidone, through Phase 3 trials, leading to a surge in share price. Community discussions revolve around the potential for further gains, concerns about dilution, and the stock's volatile price action. Some traders are betting on a continued run, while others remain wary of a potential pullback.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

TERN is trending as investors analyze recent analyst ratings, upcoming catalysts related to their CML and obesity programs, and a strong cash position lasting into 2028. Unusual options activity and insider buying have also caught the attention of traders, though some express concern over lack of recent news and data. Community members are actively discussing potential buyout scenarios and comparing TERN's prospects to others in the GLP-1 space.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending as investors discuss NAV erosion and debate the merits of its high-yield, covered call strategy amid market volatility. Concerns about the fund's management and the impact of share dilution on its price are also circulating within the community. Despite some expressing frustration, others remain committed, focusing on the potential for long-term income through weekly dividend payouts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Glucotrack Inc. (GCTK), a medical technology company specializing in diabetes management solutions, attracted significant investor interest after its shares rose by over 144% on Friday afternoon.&nbsp;On Thursday, the company announced a new financing arrangement with Sixth Borough Capital Fund LP. This agreement could provide the company with up to $20 million in equity capital over the next two years, depending on various regulatory and market conditions.On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/GCTK">Glucotrack stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume levels also shifted to ‘extremely high’ from ‘low’ levels in the last 24 hours.<figure class="image"><img style="aspect-ratio:942/113;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_12_133920_png_26d362bae8.webp" alt="GCTK’s Sentiment Meter and Message Volume as of 01:30 p.m. ET on Sep. 12, 2025 | Source: Stocktwits" width="942" height="113"><figcaption>GCTK’s Sentiment Meter and Message Volume as of 01:30 p.m. ET on Sep. 12, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced a 1,800% surge in user message count as of Friday morning. Stocktwits users commended the investment move.&nbsp;<stembedurl>https://stocktwits.com/HUBC1/message/628487656</stembedurl><stembedurl>https://stocktwits.com/ArdentInvestor/message/628487338</stembedurl>The deal includes a purchase agreement and a related registration rights agreement. The agreement grants Glucotrack the right, but not the obligation, to issue and sell shares of its common stock valued at up to $20 million. This offering can be executed incrementally, at the company's discretion, within a 24-month window following the commencement date.This financing vehicle provides Glucotrack with a flexible means to raise capital when needed, enabling it to support product development, commercialization, or general operations.&nbsp;For the second quarter, the company’s net loss increased to $4.75 million, compared to a loss of $4.48 million in the same period last year. Cash and equivalents as of June 30 totaled $9.5 million.&nbsp;Glucotrack stock has lost over 97% of its value year-to-date and 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/opendoor-chairman-keith-rabois-plans-massive-layoffs/chw8v8XRdDA">Opendoor Chairman Keith Rabois Plans Massive Layoffs: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Glucotrack Stock Just Rose Over 123% Today: Here’s An Important Update

Glucotrack announced a new financing arrangement with Sixth Borough Capital Fund LP on Thursday.

Equity

Glucotrack announced a new financing arrangement with Sixth Borough Capital Fund LP on Thursday.


Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among healthcare names on Stocktwits.GlucoTrack (GCTK)GlucoTrack posted the highest increase in retail chatter, with message volume surging 3,700% over the past seven days. As of late Sunday, sentiment remained ‘bullish’ among retail traders.On July 8, the company announced the repurchase of over 90% of its Series A Warrants, funded with cash on hand.&nbsp;The move followed last month’s disclosure of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glucotrack-announces-positive-results-from-implantable-blood-glucose-monitor-study/chmJoJwRREo">positive results</a> from its first-in-human clinical study of its continuous blood glucose monitor (CBGM).The implantable device demonstrated 99% data capture, strong accuracy, and no serious adverse events. Designed for a three-year lifespan, the CBGM measures blood glucose directly, not interstitial fluid, and requires no on-body wearable.&nbsp;A long-term feasibility study is expected to launch in Q3 2025.<a href="https://stocktwits.com/symbol/GCTK">GCTK’s stock</a> has declined 98.5% so far in 2025.Sarepta Therapeutics (SRPT)Sarepta saw a 1,991% increase in message volume over the past week, with sentiment remaining ‘extremely bullish’ as of late Sunday, despite mounting regulatory concerns.On July 19, shares plunged over 26% in midday trading after FDA Commissioner Marty Makary said the agency is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-taking-a-hard-look-to-at-whether-sarepta-gene-therapy-elevidys-should-remain-on-the-market/ch8kDByR5qt">“taking a hard look”</a> at whether Sarepta’s gene therapy, Elevidys, should stay on the market.The company disclosed a third patient death on July 18, involving a 51-year-old participant in a limb-girdle muscular dystrophy trial using a similar viral vector to Elevidys. Two earlier deaths were already under FDA investigation. Reuters reported the agency plans to request a voluntary halt to Elevidys' shipments.Amid the fallout,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">analysts criticized Sarepta</a> for not disclosing the fatality earlier, particularly during a recent business update where it announced a 500-job layoff and $400 million in cost cuts.&nbsp;The company has since paused shipments to non-ambulatory patients and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-surges-after-hours-as-it-slashes-500-jobs-amid-fda-black-box-warning-for-gene-therapy-retail-eyes-rebound/ch8KR0HR5oM">agreed to a black box warning</a> for Elevidys, citing the risk of acute liver failure.<a href="https://stocktwits.com/symbol/SRPT">SRPT’s stock</a> has declined 88.7% so far in 2025.TNF Pharmaceuticals (TNFA)TNF Pharma recorded a 1,900% rise in message volume over the past seven days on Stocktwits, with sentiment labeled ‘extremely bullish’ as of late Sunday.Although there was no specific news catalyst driving the buzz last week, the momentum has been strong since last month when TNFA announced a Compassionate Use collaboration with the DADA2 Foundation to study isomyosamine as a treatment for DADA2, a rare pediatric autoinflammatory disorder.In April,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tnf-pharmaceuticals-to-use-ai-to-recruit-patients/chQSz8ARbXp">TNFA partnered with Renova Health</a> to apply AI and machine learning to optimize patient recruitment. The company is analyzing data from 30,000 patients to identify high-risk cohorts, particularly for interventions related to inflammation and side effects of GLP-1 therapy.TNFA’s pipeline includes two drug platforms: isomyosamine, which regulates inflammatory pathways, and Supera-CBD, which targets chronic pain, addiction, and epilepsy.<a href="https://stocktwits.com/symbol/TNFA">TNFA’s stock</a> has declined 92.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-stealthily-hiked-prices-on-everyday-essentials-as-trump-tariffs-bit-report/ch8qvlTR5Ae">Amazon Stealthily Hiked Prices On Everyday Essentials As Trump Tariffs Bit: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GlucoTrack (GCTK), Sarepta Therapeutics (SRPT), and TNF Pharmaceuticals (TNFA) recorded the highest increases in message volume among healthcare names on Stocktwits. (Photo credit: Getty Images)

GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why

GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.

Shares of Glucotrack, Inc. (GCTK) traded 32% higher on Wednesday afternoon after the company announced that its first-in-human clinical study for its investigational continuous blood glucose monitor (CBGM) yielded positive results.The medical device company’s CBGM demonstrated excellent accuracy, a 99% data capture rate, and no procedure or device-related serious adverse events, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://glucotrack.com/glucotrack-and-onetwo-analytics-present-positive-final-results-of-first-in-human-study-for-continuous-blood-glucose-monitor-at-american-diabetes-associations-85th-scientific-sessions/">said</a>.Glucotrack’s CBGM is a long-term, implantable system that continually measures glucose from blood rather than interstitial fluid with a sensor designed for a 3-year life and no on-body wearable component.It aims to eliminate the lag time associated with traditional continuous glucose monitoring systems and is connected to subcutaneous electronics that communicate with a mobile application.The in-human study for the CBGM was conducted between Dec. 13, 2024, and Jan. 31, 2025, and included ten participants with either Type 1 or Type 2 diabetes who were on intensive insulin therapy.The insertion and removal procedures were performed by interventional cardiologists.Following the device placement, each participant underwent inpatient observation for 4 days. During this period, frequent blood sampling and glucose tolerance tests were conducted to assess device performance.The system remained in place throughout the study period and was removed successfully at study completion, with patients then followed for 7 days post-removal.Glucotrack now expects to initiate a long-term early feasibility study in Q3 2025, which will evaluate safety and performance of the monitor over an extended period.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GCTK">GCTK</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours to its highest levels in 3 months while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_25_at_12_52_09_PM_png_991ddcc4e4.webp" alt="GCTK's Sentiment Meter and Message Volume as of 12:50 p.m. ET on June 25, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>GCTK's Sentiment Meter and Message Volume as of 12:50 p.m. ET on June 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for Glucotrack being approached by big pharmaceutical companies for either purchase or partnerships following the news.<stembedurl>https://stocktwits.com/Barrister/message/618976594</stembedurl>GCTK stock is down by about 98% this year and has erased nearly all of its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-stock-slumps-after-fda-opens-probe-into-patient-death-analyst-sounds-alarm/chmJnVnRREn">Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A woman holds an insulin pen with an exposed injection needle. Photo: Hannes P. Albert/dpa (Photo by Hannes P Albert/picture alliance via Getty Images)

Glucotrack Announces Positive Results From Its Implantable Blood Glucose Monitor Study: Retail Sentiment Hits 3-Month High

The company’s continuous blood glucose monitor demonstrated excellent accuracy, a 99% data capture rate, and no procedure or device-related serious adverse events, the company said.

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

GlucoTrack Shares Market Research Insights Publicly

GlucoTrack (GCTK) just unveiled an announcement. Glucotrack, Inc. has released a press statement on August 15, 2024, sharing insights from recent m...

GlucoTrack And 2 Other Stocks Under $1 Insiders Are Buying

Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now

MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The...

GlucoTrack announces increase sensory longevity for CBGM

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announced Implantable Continuous Blood Glucose Monitor technology could...

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now

MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024...

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$6.65
Prev Close	$6.91
Open	$6.55
Dividend Yield	0.00%
50-Day Moving Average	$6.20
Beta	0.92
Avg. Volume	4M
PE Ratio	0.00

52-Week High	$2,928.00
52-Week Low	$4.22
Market Capitalization	$6.29M
EPS (Annual)	-$4,106.41
Price to Book	0.90
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GCTK
GlucoTrack Inc

Feed

News

Sentiment

Fundamentals

Info

Latest GCTK News

GCTKGlucoTrack Inc